Reverse DCF
What growth does the market imply for JAGSNPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
13.2% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹210
Historical Growth
0.2%
FCF Yield
3.32%
Price / FCF
30.2x
Plain English
To justify today's price of ₹209.63, JAGSNPHARM.NS needs to grow its free cash flow at 13.2% per year for the next 10 years. That is 13.0% faster than its historical growth rate of 0.2%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 0.2% | ₹78 | -63.0% |
| Half implied | 6.6% | ₹125 | -40.3% |
| GDP rate | 10.0% | ₹162 | -22.8% |
| Implied | 13.2% | ₹210 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 0.2% growth, the model values JAGSNPHARM at ₹78, below today's ₹210.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.